Stockscreener 앱 받기
9.28
15.57%
1.25
시간 외 거래:
9.38
0.10
+1.08%
전일 마감가:
$8.03
열려 있는:
$8.01
하루 거래량:
3.86M
Relative Volume:
1.47
시가총액:
$917.32M
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-19.74
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
+30.98%
1개월 성능:
+1.87%
6개월 성능:
-38.05%
1년 성능:
-32.31%
1일 변동 폭
$7.97
$9.325
1주일 범위
$6.66
$9.325
52주 변동 폭
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.28 | 793.75M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Behavioral Patterns of SPRY and Institutional Flows - news.stocktradersdaily.com
Is ARS Pharmaceuticals Inc. stock supported by strong fundamentals2025 Key Highlights & Precise Buy Zone Tips - newser.com
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Earnings Overview Summary & Consistent Growth Stock Picks - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollarPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery play2025 Market Trends & Accurate Buy Signal Alerts - newser.com
Can ARS Pharmaceuticals Inc. hit a new high this monthJuly 2025 Summary & Fast Momentum Entry Tips - newser.com
ARS Pharmaceuticals Inc. stock outlook for YEARQuarterly Growth Report & High Accuracy Buy Signal Tips - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by ARS Investment Partners LLC - MarketBeat
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Gold Moves & AI Enhanced Trading Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analysts2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
ARS Pharmaceuticals, Inc. (SPRY) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ARS Pharmaceuticals Insider Sold Shares Worth $1,476,147, According to a Recent SEC Filing - MarketScreener
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks - Yahoo Finance
Applying chart zones and confluence areas to ARS Pharmaceuticals Inc.Quarterly Portfolio Report & Weekly Setup with ROI Potential - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Dollar Strength & Risk Managed Investment Strategies - newser.com
Why ARS Pharmaceuticals Inc. stock could see breakout soonPortfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
ARS Pharmaceuticals targets renewed growth in 2026 as neffy adoption accelerates and new global launches begin - MSN
Multi factor analysis applied to ARS Pharmaceuticals Inc.2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could rally in 2025Portfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Dorsey, ARS Pharma COO, sells $190k in SPRY stock By Investing.com - Investing.com Canada
Insider Sell Alert: Brian Dorsey Sells 21,828 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
ARS Pharma CBO Chakma sells shares worth $1.47 million By Investing.com - Investing.com Canada
Dorsey, ARS Pharma COO, sells $190k in SPRY stock - Investing.com
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
COO Dorsey Sells 21,828 ($190K) Of ARS Pharmaceuticals Inc [SPRY] - TradingView
Dir Shah Gifts 350,000 Of ARS Pharmaceuticals Inc [SPRY] - TradingView
Reversal indicators forming on ARS Pharmaceuticals Inc. stockJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):